Demonstrated effectiveness against coronaviruses in preclinical studies.
Founders
Joshua McClure
Company Description
Maxwell Biosciences is developing a first-in-class, peptidomimetic drug platform that outputs low-molecular weight compounds designed to functionally mimic human peptides for the treatment of disease. Their biomimetic therapeutics have been shown to be effective against all coronaviruses tested, including SARS-CoV-2, and are well tolerated in human tissues.
Market
Pharmaceuticals
Location
Austin,
Texas,
USA
Coinvestors
DecentraNet, Harvard Business School Angels, Joseph Ventures, Keiretsu Forum, Star Lake Bioventures